The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

Published:2009-02-03 Issue:1 Volume:118 Page:125-130
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Bijl Monique J.,van Schaik Ron H. N.,Lammers Laureen A.,Hofman Albert,Vulto Arnold G.,van Gelder Teun,Stricker Bruno H. Ch.,Visser Loes E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-0272-2.pdf

Reference25 articles.

1. Louwman WJ, Voogd AC, van Dijck JA et al (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19(1):97–106. doi: 10.1007/s10552-007-9075-8

2. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609–1618. doi: 10.1056/NEJM199811263392207

3. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi: 10.1016/S0140-6736(05)66544-0

4. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75(2):305–316

5. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758–1764

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer;Journal of Pharmaceutical and Biomedical Analysis;2024-01

2. Impact of CYP2D6 polymorphisms on the efficacy of tamoxifen in Iraqi women with breast cancer;Journal of Contemporary Medical Sciences;2023-12-26

3. Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors;The Journal of Clinical Pharmacology;2022-04-19

4. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis;Expert Reviews in Molecular Medicine;2022

5. Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients;Frontiers in Pharmacology;2021-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3